PeptideCompareChitomur — EU research guide.
Chitomur is a Khavinson-series peptide bioregulator formulated from bladder tissue extract, proposed to support urothelial cell function. Unlike the synthetic tetrapeptides in the same family, it is a natural peptide complex (cytomedin) without one single defined amino acid sequence — closer in concept to Thymalin, which PeptideCompare already tracks, than to a synthetic compound like Epitalon.
What is Chitomur?
Chitomur is a Khavinson-series peptide bioregulator formulated from bladder tissue extract, proposed to support urothelial cell function. Unlike the synthetic tetrapeptides in the same family, it is a natural peptide complex (cytomedin) without one single defined amino acid sequence — closer in concept to Thymalin, which PeptideCompare already tracks, than to a synthetic compound like Epitalon.
What does the research show?
Published research is limited to small Eastern European cohort studies in urogenital aging contexts. No independently replicated controlled trials are publicly available as of mid-2026, and mechanism-of-action data is sparse compared with the synthetic short peptide bioregulators in the same series.
EU legal status
Not approved as a medicine anywhere in the EU. Available only from a small number of specialist Eastern European-linked research vendors.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Chitomur is not yet in our price comparison
We expand EU supplier coverage every month.
References
- The only randomised, placebo-controlled human trial found (n=50, 15 days). The citation was taken from a producer-affiliated page and the journal article was not opened; two such pages agree on the design and numbers. It is a small trial by the developing group. Gomberg VG, Ryzhak AP, Lyutov RV. Use of a peptide geroprotector (Chitomur) in elderly and senile patients with prostatic hyperplasia (title translated from Russian). Uspekhi Gerontologii (Adv Gerontol). 2013;26(3):476-480. Citation taken from a producer-affiliated web page; the journal article itself was not opened. Source
- Unpublished manufacturer report posted by a vendor (59 participants, 2011). It is included for transparency only: no peer review, no full methods, and it is not independent evidence. Saint Petersburg Institute of Bioregulation and Gerontology Medical Center. Report of clinical study of the peptide bioregulator Chitomur, March-November 2011 (unpublished manufacturer report as posted by a vendor; no journal citation). Source
- Group review of animal studies of peptide bioregulators. It lists bladder-derived preparations only among many tissues, gives no product-specific data for Chitomur, and all data come from the originating group. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Message 1: Results of experimental studies. Adv Gerontol. 2013;3(3):225-235. DOI